...
首页> 外文期刊>Infection and Drug Resistance >Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis
【24h】

Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis

机译:耐多药结核患者的痰细菌学转换和治疗结果

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Multidrug-resistant tuberculosis (MDR-TB) requires long-term treatment, has a high fatality rate, and constitutes a global threat. Earlier detection of treatment failure is required to predict therapeutic efficacy. Patients and methods: We enrolled MDR-TB patients consecutively from January 2011 through December 2012 in Lianyungang, China. Sputum smear microscopy tests and sputum cultures were performed once a month for the first 6 months following initiation of antituberculosis treatment and once every 2 months thereafter until the end of therapy. The sensitivity, specificity and area under the receiver operating characteristic curve (AUC) were used with a 95% CI to estimate the role of sputum bacteriology conversion in predicting treatment outcomes. Results: Among the 92 MDR-TB patients enrolled in this study, 40.2% had poor treatment outcomes. The median initial sputum bacteriology conversion time was 1 month. Patients having 2-month sputum smear conversions (adjusted odds ratio [OR]: 7.19, 95% CI: 2.60–19.84) or culture conversions (adjusted OR: 2.88, 95% CI: 1.11–7.45) were more likely to experience good outcomes. The sensitivity and specificity obtained when using two-month sputum smear conversions to predict treatment outcomes were 67.6% (95% CI: 50.2–82.0) and 76.4% (95% CI: 63.0–86.8), respectively. The sensitivity and specificity obtained when using 2-month culture conversions to predict treatment outcomes were 48.6% (95% CI: 32.0–65.6) and 74.5% (95% CI: 61.0–85.3), respectively. The AUC for two-month smear conversions was 0.72 (95% CI: 0.62–0.81), significantly higher than that obtained for 2-month culture conversions (0.62, 95% CI: 0.52–0.72) (Χ2 = 4.18, P = 0.041). Conclusion: The prognoses of MDR-TB patients displaying persistent sputum positivity were inferior to those for whom sputum bacteriology conversion was observed. Thus, sputum smear conversion results obtained 2 months after treatment initiation may provide a potential means for predicting MDR-TB treatment outcomes.
机译:目的:耐多药结核病(MDR-TB)需要长期治疗,病死率高,并构成全球性威胁。需要早期检测治疗失败以预测治疗效果。患者和方法:我们从2011年1月至2012年12月在中国连云港连续招募了耐多药结核病患者。在开始抗结核治疗后的头6个月,每月进行一次痰涂片镜检和痰培养,此后每2个月进行一次,直至治疗结束。接受者工作特征曲线(AUC)下的敏感性,特异性和面积与95%CI一起用于评估痰细菌学转化在预测治疗结果中的作用。结果:参加本研究的92名耐多药结核病患者中,有40.2%的治疗结果较差。中位初始痰细菌学转化时间为1个月。进行2个月痰涂片转化(调整后的优势比[OR]:7.19,95%CI:2.60-19.84)或文化转化(调整后的OR:2.88,95%CI:1.11-7.45)的患者更有可能获得良好的预后。使用两个月的痰涂片检查转换来预测治疗结果时的敏感性和特异性分别为67.6%(95%CI:50.2-82.0)和76.4%(95%CI:63.0-86.8)。使用2个月的培养转化来预测治疗结果时的敏感性和特异性分别为48.6%(95%CI:32.0–65.6)和74.5%(95%CI:61.0-85.3)。两个月涂片转化的AUC为0.72(95%CI:0.62-0.81),明显高于两个月培养物转化的AUC(0.62,95%CI:0.52-0.72)(Χ 2 = 4.18,P = 0.041)。结论:表现出持续痰阳性的耐多药结核病患者的预后要差于观察到细菌细菌学转变的患者。因此,治疗开始后2个月获得的痰涂片转化结果可能为预测MDR-TB治疗结果提供了一种潜在的手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号